253 related articles for article (PubMed ID: 30709707)
1. Hepatitis C Virus.
Pietschmann T; Brown RJP
Trends Microbiol; 2019 Apr; 27(4):379-380. PubMed ID: 30709707
[TBL] [Abstract][Full Text] [Related]
2. Hepatitis C Virus Infection Is Inhibited by a Noncanonical Antiviral Signaling Pathway Targeted by NS3-NS4A.
Vazquez C; Tan CY; Horner SM
J Virol; 2019 Dec; 93(23):. PubMed ID: 31534039
[TBL] [Abstract][Full Text] [Related]
3. The Beginning of Ending Hepatitis C Virus: A Summary of the 26th International Symposium on Hepatitis C Virus and Related Viruses.
Shin EC; Han JW; Kang W; Kato T; Kim SJ; Zhong J; Kim S; Park SH; Sung PS; Watashi K; Park JY; Windisch MP; Oh JW; Wakita T; Han KH; Jang SK
Viruses; 2020 Mar; 12(3):. PubMed ID: 32168867
[No Abstract] [Full Text] [Related]
4. Hepatitis C Viral Replication Complex.
Li HC; Yang CH; Lo SY
Viruses; 2021 Mar; 13(3):. PubMed ID: 33809897
[TBL] [Abstract][Full Text] [Related]
5. Treatment of hepatitis C virus genotype 3-infection.
Pol S; Vallet-Pichard A; Corouge M
Liver Int; 2014 Feb; 34 Suppl 1():18-23. PubMed ID: 24373074
[TBL] [Abstract][Full Text] [Related]
6. Recent Advancement of Direct-acting Antiviral Agents (DAAs) in Hepatitis C Therapy.
Das D; Pandya M
Mini Rev Med Chem; 2018; 18(7):584-596. PubMed ID: 28901852
[TBL] [Abstract][Full Text] [Related]
7. Protease Inhibitors Block Multiple Functions of the NS3/4A Protease-Helicase during the Hepatitis C Virus Life Cycle.
McGivern DR; Masaki T; Lovell W; Hamlett C; Saalau-Bethell S; Graham B
J Virol; 2015 May; 89(10):5362-70. PubMed ID: 25740995
[TBL] [Abstract][Full Text] [Related]
8. Hepatitis C virus NS5A: enigmatic but still promiscuous 10 years on!
Ross-Thriepland D; Harris M
J Gen Virol; 2015 Apr; 96(Pt 4):727-738. PubMed ID: 25481754
[TBL] [Abstract][Full Text] [Related]
9. Current status and future development of infectious cell-culture models for the major genotypes of hepatitis C virus: Essential tools in testing of antivirals and emerging vaccine strategies.
Ramirez S; Bukh J
Antiviral Res; 2018 Oct; 158():264-287. PubMed ID: 30059723
[TBL] [Abstract][Full Text] [Related]
10. Identification of drug resistance and immune-driven variations in hepatitis C virus (HCV) NS3/4A, NS5A and NS5B regions reveals a new approach toward personalized medicine.
Ikram A; Obaid A; Awan FM; Hanif R; Naz A; Paracha RZ; Ali A; Janjua HA
Antiviral Res; 2017 Jan; 137():112-124. PubMed ID: 27984060
[TBL] [Abstract][Full Text] [Related]
11. Discovery of hepatitis C virus NS5A inhibitors as a new class of anti-HCV therapy.
Lee C
Arch Pharm Res; 2011 Sep; 34(9):1403-7. PubMed ID: 21975800
[TBL] [Abstract][Full Text] [Related]
12. Understanding the molecular targets for new therapeutical agents in hepatitis c infection.
Vagu C; Sultana C; Ruţă S
Roum Arch Microbiol Immunol; 2013; 72(1):5-24. PubMed ID: 23947011
[TBL] [Abstract][Full Text] [Related]
13. Osteopontin Regulates Hepatitis C Virus (HCV) Replication and Assembly by Interacting with HCV Proteins and Lipid Droplets and by Binding to Receptors αVβ3 and CD44.
Iqbal J; Sarkar-Dutta M; McRae S; Ramachandran A; Kumar B; Waris G
J Virol; 2018 Jul; 92(13):. PubMed ID: 29669827
[TBL] [Abstract][Full Text] [Related]
14. Hepacivirus NS3/4A Proteases Interfere with MAVS Signaling in both Their Cognate Animal Hosts and Humans: Implications for Zoonotic Transmission.
Anggakusuma ; Brown RJP; Banda DH; Todt D; Vieyres G; Steinmann E; Pietschmann T
J Virol; 2016 Dec; 90(23):10670-10681. PubMed ID: 27654291
[TBL] [Abstract][Full Text] [Related]
15. A Novel Small Molecule Inhibits Hepatitis C Virus Propagation in Cell Culture.
Oraby AK; Gardner CL; Needle RF; Kofahi HM; Everard KR; Taylor NGA; Rutihinda SG; Barry JP; Hirasawa K; Georghiou PE; Russell RS
Microbiol Spectr; 2021 Sep; 9(1):e0043921. PubMed ID: 34319169
[TBL] [Abstract][Full Text] [Related]
16. Review on chemogenomic approaches towards hepatitis C viral targets.
Venkatesan A; Prabhu Dass J F
J Cell Biochem; 2019 Aug; 120(8):12167-12181. PubMed ID: 30887580
[TBL] [Abstract][Full Text] [Related]
17. An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus.
Lamarre D; Anderson PC; Bailey M; Beaulieu P; Bolger G; Bonneau P; Bös M; Cameron DR; Cartier M; Cordingley MG; Faucher AM; Goudreau N; Kawai SH; Kukolj G; Lagacé L; LaPlante SR; Narjes H; Poupart MA; Rancourt J; Sentjens RE; St George R; Simoneau B; Steinmann G; Thibeault D; Tsantrizos YS; Weldon SM; Yong CL; Llinàs-Brunet M
Nature; 2003 Nov; 426(6963):186-9. PubMed ID: 14578911
[TBL] [Abstract][Full Text] [Related]
18. Small molecule inhibitors of the hepatitis C virus-encoded NS5A protein.
Belda O; Targett-Adams P
Virus Res; 2012 Dec; 170(1-2):1-14. PubMed ID: 23009750
[TBL] [Abstract][Full Text] [Related]
19. [RESISTANCE OF HCV TO NEW DIRECT ACTING ANTIVIRALS].
Gozlan Y; Mendelson E; Ben-Ari Z; Mor O
Harefuah; 2015 Nov; 154(11):684-7, 743. PubMed ID: 26821497
[TBL] [Abstract][Full Text] [Related]
20. Identification of novel small molecule inhibitors against the NS3/4A protease of hepatitis C virus genotype 4a.
El-Sayed SM; Ali MAM; El-Gendy BEM; Dandash SS; Issac Y; Saad R; Azab MM; Mohamed MR
Curr Pharm Des; 2018; 24(37):4484-4491. PubMed ID: 30501598
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
